Back to Search Results

Cumulative risks of colorectal cancer in Han Chinese patients with Lynch syndrome in Taiwan.

School of Public Health, College of Public Health, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan. The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan. Colorectal Section, Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan. School of Medicine, Chang Gung University, Taoyuan, Taiwan. Department of Nutrition and Health Sciences, Chang Gung University of Science and Technology, Taoyuan, Taiwan. Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan. Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan. School of Public Health, College of Public Health, Taipei Medical University, 250 Wu-Hsing Street, Taipei, Taiwan. ccyeh@tmu.edu.tw. Department of Public Health, China Medical University, Taichung, Taiwan. ccyeh@tmu.edu.tw. Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. ccyeh@tmu.edu.tw. Master Program in Applied Molecular Epidemiology, College of Public Health, Taipei Medical University, Taipei, Taiwan. ccyeh@tmu.edu.tw.

Scientific reports. 2021;(1):8899
Full text from:

Other resources

Abstract

Patients with Lynch syndrome have a high risk of colorectal cancer (CRC). In this study, we estimated the age- and sex-specific cumulative risks of CRC in Han Chinese patients with Lynch syndrome caused by the pathogenic germline mutations in MLH1 or MSH2 in Taiwan. Based on 321 mutation carriers and 419 non-mutation carriers from 75 pedigrees collected in an Amsterdam criteria family registry in Taiwan, the age- and sex-specific cumulative risks of CRC in male carriers of mutation in MLH1 and MSH2 at the age of 70 years were 60.3% (95% confidence interval (CI) = 31.1%-89.9%) and 76.7% (95% CI = 37.2%-99.0%), respectively. For females, the cumulative risks of CRC at the age of 70 were estimated to be 30.6% (95% CI = 14.3%-57.7%) and 49.3% (95% CI = 21.9%-84.5%) in the carriers of MLH1 and MSH2 germline mutations, respectively. In conclusion, the cumulative risks of CRC at the age of 70 in the Han Chinese patients is higher in mutation carriers than non-mutation carriers and male mutation carriers have a higher cumulative risk of developing CRC than the female mutation carriers.

Methodological quality

Publication Type : Clinical Trial

Metadata